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Disease-modifying therapy prescription patterns
in people with multiple sclerosis by age
Yinan Zhang , Amber Salter, Shan Jin, William J. Culpepper II, Gary R. Cutter,
Mitchell Wallin and Olaf Stuve

Abstract
Background: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved
for their ability to reduce disease activity, namely clinical relapses and signal changes on
magnetic resonance imaging (MRI). Disease activity appears age dependent. Thus, the
greatest benefit would be expected in younger people with MS (PwMS) whereas benefits in the
elderly are uncertain.
Methods: Real-world data were obtained from PwMS from the North American Research
Committee on Multiple Sclerosis (NARCOMS) registry and the US Department of Veterans
Affairs Multiple Sclerosis Surveillance Registry (MSSR).
Results: 6948 PwMS were surveyed from NARCOMS, and the MSSR had 1719 participants.
In younger adult PwMS 40-years old or less, 183 (61.4%) in NARCOMS and 179 (70.5%) in the
MSSR were prescribed DMTs. Among PwMS over age 60, 1575 (40.1%) in NARCOMS and 239
(36.3%) in the MSSR were prescribed DMTs. More PwMS in the age group of 31–40 (p = 0.035)
and 41–50 (p = 0.001) in the MSSR were using DMTs compared with PwMS of the same age
groups in NARCOMS.
Conclusion: These findings suggest that DMTs are under-utilized in the younger population
and continue to be commonly prescribed in the elderly. Broader access may explain the higher
prescription rate of DMTs in US veterans.
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In clinical practice, there are a lack of data showing
DMT prescribing patterns in real-world populations
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Introduction
Treatment options for multiple sclerosis (MS) have
greatly expanded in recent years, and there are currently at least 18 approved disease-modifying therapies (DMTs) that have shown efficacy in reducing
disease activity.1,2 DMTs are most effective in
reducing clinical relapses and the formation of new
MRI lesions, both of which are age-dependent processes. With increasing age, people with MS
(PwMS) are less likely to have clinical relapses or
radiological disease activity.3,4 As a result, younger
PwMS are more likely to derive the most documented or apparent benefits from using DMTs due
to a higher likelihood of disease activity.5–7
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by age. This information is highly relevant to ascertain if PwMS in different age groups receive adequate care. The objective of this study was to
determine the frequencies of DMT prescriptions in
relation to age in the real-world setting using two
large MS registries. We hypothesize that DMTs are
prescribed for the majority of younger PwMS and
less consistently in the elderly.
Methods
NARCOMS registry
The North American Research Committee on
Multiple Sclerosis (NARCOMS) registry has
collected voluntarily reported demographic
and clinical information from PwMS since
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1996. After enrolling in the registry, participants were asked to update their information
on a semi-annual basis. The fall 2018 semiannual update survey was used to identify current DMT use (including interferon beta-1a,
interferon beta-1b, peginterferon beta-1a, glatiramer acetate, teriflunomide, fingolimod,
dimethyl fumarate, natalizumab, and ocrelizumab). The age of the participants was their
age at the survey date. The frequency and proportion of DMT prescriptions for each 10-year
age group were reported.
Multiple sclerosis surveillance registry
The Multiple Sclerosis Surveillance Registry
(MSSR) is an MS database established by the
US Veterans Health Administration (VHA) in
2013.8 Data on key demographic and clinical
variables related to MS were collected by clinicians and directly entered into the database during live or telehealth visits or telephone calls.
The MSSR has approximately 2000 PwMS at
present and features an interactive tool to pull
data based on pre-specified queries. We obtained
de-identified information on the number of
PwMS being prescribed a US Food and Drug
Administration (FDA)-approved DMT by each
10-year age group.
Ethical approval and informed consent
The NARCOMS registry was approved by the
institutional review board (IRB) at Washington
University in St. Louis (IRB#: 201610132),
and participants consent to the use of de-identified information for research. An IRB-approved
protocol within the US Department of VHA MS
Centers of Excellence (MSCoE) has been
approved by the University of Maryland IRB
[HP-00043983 MSCoE Epidemiology Core
(H-28293)] and covers the analysis of data in
the MSSR.
Statistical analysis
Analyses were conducted using SAS V9.4 statistical
software (SAS Institute Inc., Cary, NC, US). Chisquare tests were used to assess differences in DMT
use between PwMS of each age group in the two
registries, and nominal two-sided p values of 0.05 or
less were considered statistically significant.
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Results
DMT use by age in NARCOMS
Of the 6948 respondents to the NARCOMS fall
2018 update survey, 3325 (47.9%) of participants
report using DMTs, and 3623 (52.1%) participants report not using DMTs at the time of the
survey. With increasing age, the proportion of
DMT use decreased (Table 1, Figure 1). In the
age 71–80 group, less than a third (29.5%) of participants reported DMT use. Conversely, the
majority (61.4%) of younger PwMS age 40 or less
reported DMT use.
DMT use by age in MSSR
The MSSR presented information on DMT use
for 1719 PwMS as of July 2019, of whom 936
(54.5%) were currently prescribed DMTs, and
783 (45.5%) were currently not prescribed
DMTs. The proportion of PwMS prescribed
DMTs decreased with age, with over a quarter
(27.2%) of the individuals in the 71–80 age group
prescribed DMTs and over two thirds (70.5%) of
younger PwMS age 40 or less prescribed DMTs
(Table 1, Figure 2).
More PwMS in the age group of 31–40 (p = 0.035)
and 41–50 (p = 0.001) in the MSSR were prescribed DMTs (70.5% and 72.5% respectively)
compared with PwMS of the same age groups in
NARCOMS (61.5% and 62.7% respectively).
There were no differences in the frequency of
DMT use between all other age groups in the two
databases.
Discussion
Real-world data from NARCOMS and the MSSR
showed decreasing frequencies of DMT use with
age. Nevertheless, almost a third of younger PwMS
below age 40 appear not to be using DMTs despite
widespread recognition of the importance of early
treatment in MS.9,10 Other studies have shown that
early treatment delays time to reach diagnosis of
clinically definite MS in people with clinically isolated syndrome, as well as disability accumulation
in PwMS.11,12 In a study that surveyed 507 relapsing–remitting MS patients in the US, the most frequently reported barriers to DMT use included
insurance authorization requirements and high
out-of-pocket costs.13 Our own observations
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Table 1. Current use of disease-modifying therapies (DMTs) according to age groups based on data from the North American
Research Committee on Multiple Sclerosis (NARCOMS) registry and the Multiple Sclerosis Surveillance Registry (MSSR).
Age
group

NARCOMS
Total
(n = 6948)

MSSR
Female
(%)

Not taking DMT
(n = 3623) (%)

Taking DMT
(n = 3325) (%)

Total
(n = 1719) (%)

p value
Female (%)

Not taking DMT
(n = 783) (%)

Taking DMT
(n = 936) (%)

21–30

36

33 (91.7)

14 (38.9)

22 (61.1)

54

17 (31.5)

16 (29.6)

38 (70.4)

0.361

31–40

262

226 (86.3)

101 (38.5)

161 (61.5)

200

78 (39.0)

59 (29.5)

141 (70.5)

0.035

41–50

781

669 (85.7)

291 (37.3)

490 (62.7)

342

132 (38.6)

94 (27.5)

248 (72.5)

0.001

51–60

1943

1612 (83.0)

866 (44.6)

1077 (55.4)

464

140 (30.2)

194 (41.8)

270 (58.2)

0.188

61–70

2760

2188 (79.3)

1508 (54.6)

1252 (45.4)

469

78 (16.7)

276 (58.9)

193 (41.1)

0.178

71–80

1039

763 (73.4)

732 (70.5)

307 (29.5)

162

13 (8.0)

118 (72.8)

44 (27.2)

0.708

81+

127

95 (74.8)

111 (87.4)

16 (12.6)

28

26 (92.9)

2 (7.1)

0.541

3 (10.7)

The p values are reported from Chi-square tests used to assess differences in DMT use between PwMS of each age group in the two registries.
PwMS, people with multiple sclerosis.

suggest more consistent access to health care and
DMTs as a potential explanation for the slightly
higher rate in US veterans compared with PwMS
in NARCOMS, which is a more general population. In addition, it is likely that more young PwMS
in NARCOMS are not on treatment due to family
planning and pregnancy compared with participants in MSSR who are predominantly male.
Nevertheless, this does not explain the almost 30%

of younger PwMS who are not being prescribed
DMTs. Still, the overall similarity in rates and patterns by age suggest the two databases are reasonably consistent assessments of DMT use in PwMS
by age. Costs of DMTs are uniformly lower in the
integrated VA health care system and similar to
rates in Canada due in part to the ability to negotiate prices with the pharmaceutical industry.14 An
observational study of 10,698 Canadian PwMS

Figure 1. Current use of disease-modifying therapies (DMTs) in people with multiple sclerosis (PwMS) by
age groups based on data from the North American Research Committee on Multiple Sclerosis (NARCOMS)
registry.
journals.sagepub.com/home/tan
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Figure 2. Current use of disease-modifying therapies (DMTs) in people with multiple sclerosis (PwMS) by age
groups based on data from the US Department of Veterans Affairs (VA) Multiple Sclerosis Surveillance Registry
(MSSR).

identified an association between increasing number of comorbidities and lower likelihood of DMT
use.15 The investigators attributed the findings to
hesitancy by PwMS and providers towards multidrug use and the perception of decreased treatment
benefits in the setting of other chronic health conditions. Additional reasons for not using DMTs
including side effects, disease-related stress, and
the perception of a mild disease course have also
been identified in studies.16,17 Addressing the
undertreatment of younger PwMS who are more
likely to benefit from DMT use requires ongoing
efforts to improve DMT access and better understanding of treatment expectations.
In contrast to young PwMS, over a third of older
PwMS above age 60 in both databases were
treated with DMTs. With earlier diagnosis of MS
and improved care, PwMS are growing both in
number and age. In North America, the peak
prevalence of MS is in the late 50s.18,19 With prolonged DMT use, there is an increased risk of
adverse reactions especially in older PwMS who
are more susceptible to established side effects of
DMTs, including infections and lymphopenia as
well as multi-drug interactions.20–22 In addition,
disease activity in MS diminishes due to immune
senescence, and relapses are less frequent in
PwMS over age 60 compared with those who are
younger.23 The evidence for DMT efficacy in
4

PwMS is largely from clinical trials of MS DMTs,
but these trials tend to exclude individuals over
age 55. Subgroup analyses of clinical trial data
have shown diminished DMT efficacy in PwMS
older than age 40 compared with those younger,6
and a meta-analysis of clinical trials of DMTs
showed decreased inhibition of disease progression with aging.24 While these studies suggests
decreased efficacy of DMTs in elderly PwMS,
there is a need for randomized controlled trials to
definitively address the topic.
The continued use of DMTs in the elderly may be
the result of the perceived notion that disease inactivity is due to treatment rather than the natural
disease course with aging despite lower projected
benefits in the elderly.25 Further contributing to
the hesitancy to discontinue DMT may be a concern of rebound disease activity with some
agents.26,27 The safety of DMT use in the elderly
remains unclear and deserves more rigorous study.
While recent retrospective data suggest relative
safety in discontinuing DMTs in older patients
without disease activity,28–30 these findings were
not universal, and cases of disease worsening after
stopping DMTs have been reported.31 The currently ongoing DISCOMS trial is expected to
address whether DMTs can be safely discontinued
in stable MS patients over age 55.32 Nevertheless,
PwMS who are doing well may be very reluctant to
journals.sagepub.com/home/tan
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stop therapy, and this too can have detrimental
effects if mandated by payors or clinicians without
taking patient perceptions into account.
Some limitations are present in this study.
Participation in the NARCOMS registry is voluntary, which may be subject to responder bias
resulting in differences between the registry’s MS
population and the general MS population.
However, validation of diagnoses in NARCOMS
has been previously established,33 and reports and
findings from NARCOMS have mirrored clinical
and trial data on smaller cohorts repeatedly.
Finally, the consistency of responses between
NARCOMS and the MSSR increase our confidence that these age-related findings are indeed
valid. While the MSSR comprises a US veteran
population with different characteristics than the
general population, several relevant characteristics, including age of MS diagnosis and disease
phenotype distribution, are similar to the general
MS population.34 Lastly, the present data do not
include reasons for prescribing or not prescribing
DMTs to PwMS. Despite differences in methodology of data collection in NARCOMS and the
MSSR as well as their population differences,
there were no significant differences in percentage of PwMS using DMTs by age among older
PwMS in both large databases that would have
ample power to see meaningful differences. A
higher percentage of younger PwMS in the MSSR
were treated compared with NARCOMS, but
this might be the more standardized treatment
approach with the VA compared with general
practice neurologists and specialists.
DMTs for MS are more frequently used at
younger ages when there is likely higher disease
activity, yet a substantial proportion of younger
PwMS remains untreated. As the probability of
active disease declines with age and susceptibility
to side effects increases, the risk versus benefit
ratio of continuing DMTs in the elderly very
likely diminishes. Further studies are needed to
understand and address lack of treatment in
young adults with MS as well as the reasons for
persistent DMT use in the elderly.
Author contributions
YZ, AS, MW, and OS contributed to the study
design. AS, SJ, WC, and MW participated in data
collection. YZ, AS, SJ, WC, MW participated in
data analysis. The first draft was written by YZ
with input from all authors. All authors contribjournals.sagepub.com/home/tan

uted to the review and approval of the final manuscript version for submission.
Conflict of interest statement
Y Zhang, A Salter, S Jin, W Culpepper, and M
Wallin declare no competing interests related to
this study. G Cutter has participated on datamonitoring and safety-monitoring boards for
Avexis Pharmaceuticals, Biolinerx, Brainstorm
Cell Therapeutics, CSL Behring, Galmed
Pharmaceuticals, Horizon Pharmaceuticals,Hisun
Pharmaceuticals, Mapi Pharmaceuticals, Merck,
Merck/Pfizer, Opko Biologics, Neurim, Novartis,
Ophazyme,
Sanofi-Aventis,
Reata
Pharmaceuticals, Receptos/Celgene, Teva pharmaceuticals, Vivus, NHLBI (Protocol Review
Committee), NICHD (OPRU oversight committee); participated in consulting or advisory boards
for Biogen, Click Therapeutics, Genzyme,
Genentech, Gilgamesh Pharmaceuticals, GW
Pharmaceuticals, Klein-Buendel Incorporated,
Medimmune, Medday, Novartis, Osmotica
Pharmaceuticals, Perception Neurosciences,
Recursion Pharmaceuticals, Roche, Somahlution,
TG Therapeutics; is employed by the University
of Alabama at Birmingham and President of
Pythagoras, Inc. a private consulting company
located in Birmingham AL. O Stuve serves on the
editorial boards of Therapeutic Advances in
Neurological Disorders and on data-monitoring
committees for Genentech-Roche, Pfizer, and TG
Therapeutics without monetary compensation,
advised EMD Serono, Celgene, Genentech, TG
Therapeutics, and Genzyme, and receives grant
support from Sanofi Genzyme and EMD Serono.
Funding
The authors received no financial support for the
research, authorship, and/or publication of this
article.
ORCID iDs
Yinan Zhang
https://orcid.org/0000-00019934-4564
Olaf Stuve
https://orcid.org/0000-0002-04696872

References
1. Tintore M, Vidal-Jordana A and Sastre-Garriga
J. Treatment of multiple sclerosis - success from
bench to bedside. Nat Rev Neurol 2019; 15:
53–58.

5

Therapeutic Advances in Neurological Disorders 14
2. Li H, Hu F, Zhang Y, et al. Comparative efficacy
and acceptability of disease-modifying therapies
in patients with relapsing-remitting multiple
sclerosis: a systematic review and network metaanalysis. J Neurol. Epub ahead of print 25 May
2019. DOI: 10.1007/s00415-019-09395-w.
3. Scalfari A, Lederer C, Daumer M, et al. The
relationship of age with the clinical phenotype in
multiple sclerosis. Mult Scler 2016; 22: 1750–
1758.
4. Tremlett H, Zhao Y, Joseph J, et al. Relapses in
multiple sclerosis are age- and time-dependent. J
Neurol Neurosurg Psychiatry 2008; 79: 1368–1374.
5. Zeydan B and Kantarci OH. Impact of age on
multiple sclerosis disease activity and progression.
Curr Neurol Neurosci Rep 2020; 20: 24.
6. Signori A, Schiavetti I, Gallo F, et al. Subgroups
of multiple sclerosis patients with larger treatment
benefits: a meta-analysis of randomized trials. Eur
J Neurol 2015; 22: 960–966.
7. Gartner J, Chitnis T, Ghezzi A, et al. Relapse rate
and MRI activity in young adult patients with
multiple sclerosis: a post hoc analysis of phase
3 fingolimod trials. Mult Scler J Exp Transl Clin
2018; 4: 2055217318778610.
8. Wallin MT, Whitham R, Maloni H, et al. The
Multiple Sclerosis Surveillance Registry: a novel
interactive database within the Veterans Health
Administration. Fed Pract 2020; 37: S18–S23.
9. Cerqueira JJ, Compston DAS, Geraldes R,
et al. Time matters in multiple sclerosis: can
early treatment and long-term follow-up ensure
everyone benefits from the latest advances in
multiple sclerosis? J Neurol Neurosurg Psychiatry
2018; 89: 844–850.
10. Giovannoni G, Butzkueven H, Dhib-Jalbut S,
et al. Brain health: time matters in multiple
sclerosis. Mult Scler Relat Disord 2016; 9(Suppl. 1):
S5–S48.
11. Armoiry X, Kan A, Melendez-Torres GJ, et al.
Short- and long-term clinical outcomes of use of
beta-interferon or glatiramer acetate for people
with clinically isolated syndrome: a systematic
review of randomised controlled trials and
network meta-analysis. J Neurol 2018; 265:
999–1009.
12. Chalmer TA, Baggesen LM, Nørgaard M, et al.;
Danish Multiple Sclerosis Group. Early versus
later treatment start in multiple sclerosis: a
register-based cohort study. Eur J Neurol 2018;
25: 1262-e110.
13. Simacek KF, Ko JJ, Moreton D, et al. The impact
of disease-modifying therapy access barriers on

6

people with multiple sclerosis: mixed-methods
study. J Med Internet Res 2018; 20: e11168.
14. Hartung DM, Bourdette DN, Ahmed SM, et al.
The cost of multiple sclerosis drugs in the US
and the pharmaceutical industry: too big to fail?
Neurology 2015; 84: 2185–2192.
15. Zhang T, Tremlett H, Leung S, et al.; CIHR
Team in the Epidemiology and Impact of
Comorbidity on Multiple Sclerosis. Examining
the effects of comorbidities on disease-modifying
therapy use in multiple sclerosis. Neurology 2016;
86: 1287–1295.
16. Schoor R, Bruce A, Bruce J, et al. Reasons for
nonadherence and response to treatment in
an adherence intervention trial for relapsingremitting multiple sclerosis patients. J Clin
Psychol 2019; 75: 380–391.
17. Grytten N, Aarseth JH, Espeset K, et al. Stoppers
and non-starters of disease-modifying treatment
in multiple sclerosis. Acta Neurol Scand 2013;
127: 133–140.
18. Kingwell E, Zhu F, Marrie RA, et al. High
incidence and increasing prevalence of multiple
sclerosis in British Columbia, Canada: findings
from over two decades (1991–2010). J Neurol
2015; 262: 2352–2363.
19. Wallin MT, Culpepper WJ, Campbell JD, et al.;
US Multiple Sclerosis Prevalence Workgroup.
The prevalence of MS in the United States: a
population-based estimate using health claims
data. Neurology 2019; 92: e1029–e1040.
20. Luna G, Alping P, Burman J, et al. Infection risks
among patients with multiple sclerosis treated
with fingolimod, natalizumab, rituximab, and
injectable therapies. JAMA Neurol 2020; 77:
184–191.
21. Grebenciucova E and Berger JR.
Immunosenescence: the role of aging in the
predisposition to neuro-infectious complications
arising from the treatment of multiple sclerosis.
Curr Neurol Neurosci Rep 2017; 17: 61.
22. Goldman MD, Dwyer L, Coleman R, et al.
Patient-specific factors modulate leukocyte
response in dimethyl fumarate treated MS
patients. PLoS One 2020; 15: e0228617.
23. Vaughn CB, Jakimovski D, Kavak KS, et al.
Epidemiology and treatment of multiple sclerosis
in elderly populations. Nat Rev Neurol 2019; 15:
329–342.
24. Weideman AM, Tapia-Maltos MA, Johnson K,
et al. Meta-analysis of the age-dependent efficacy
of multiple sclerosis treatments. Front Neurol
2017; 8: 577.

journals.sagepub.com/home/tan

Y Zhang, A Salter et al.
25. Schwehr NA, Kuntz KM, Enns EA, et al.;
BeAMS Study group. Informing medication
discontinuation decisions among older adults
with relapsing-onset multiple sclerosis. Drugs
Aging 2020; 37: 225–235.

30. Yano H, Gonzalez C, Healy BC, et al.
Discontinuation of disease-modifying therapy
for patients with relapsing-remitting multiple
sclerosis: effect on clinical and MRI outcomes.
Mult Scler Relat Disord 2019; 35: 119–127.

26. O’Connor PW, Goodman A, Kappos L, et al.
Disease activity return during natalizumab
treatment interruption in patients with multiple
sclerosis. Neurology 2011; 76: 1858–1865.

31. Berkovich R. Clinical and MRI outcomes after
stopping or switching disease-modifying therapy
in stable MS patients: a case series report. Mult
Scler Relat Disord 2017; 17: 123–127.

27. Hatcher SE, Waubant E, Nourbakhsh B, et al.
Rebound syndrome in patients with multiple
sclerosis after cessation of fingolimod treatment.
JAMA Neurol 2016; 73: 790–794.

32. ClinicalTrials.gov. Discontinuation of disease
modifying therapies (DMTs) in multiple sclerosis
(MS) (DISCOMS). Identifier NCT03073603.
Bethesda, MD: National Library of Medicine
(US), 2017.

28. Kaminsky A-L, Omorou AY, Soudant M, et al.
Discontinuation of disease-modifying treatments
for multiple sclerosis in patients aged over 50
with disease inactivity. J Neurol 2020; 267:
3518–3527.
29. Hua LH, Fan TH, Conway D, et al.
Discontinuation of disease-modifying therapy in
patients with multiple sclerosis over age 60. Mult
Scler 2019; 25: 699–708.

journals.sagepub.com/home/tan

33. Marrie RA, Cutter G, Tyry T, et al. Validation
of the NARCOMS registry: diagnosis. Mult Scler
2007; 13: 770–775.
34. Culpepper WJ, Wallin MT, Magder LS, et al.
VHA multiple sclerosis surveillance registry and
its similarities to other contemporary multiple
sclerosis cohorts. J Rehabil Res Dev 2015; 52:
263–272.

Visit SAGE journals online
journals.sagepub.com/
home/tan

SAGE journals

7

